A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)

Trial Profile

A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Mirikizumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms SERENITY
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 08 Nov 2016 Planned End Date changed from 1 Jun 2020 to 1 Apr 2021.
    • 08 Nov 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top